PCR Detection of CPE in 50 Minutes

Xpert® Carba-R

 
 

Carbapenemase-producing Enterobacterales (CPE) pose one of the greatest challenges antimicrobial resistance (AMR) to healthcare systems, and national elective recovery plans.1,2

 

CPE have become resistant to all or nearly all available antibiotics, are spread rapidly, and have both high infection and mortality rates.3,4,5

 

Early identification of patients colonised or infected with CPE can help minimise transmission and inform early interventions to prevent invasive infections.6

 

 

Who Should be Tested?

Patients should have a clinical risk assessment on admission, readmission or transfer to determine those at higher risk of CPE colonisation or infection, in particular:3

  • Previous inpatients in any hospital (including local and aboard hospitals)
  • Patients entering high risks settings, e.g., ICU
  • Patients requiring multiple hospital treatments, e.g., dialysis
  • Patients previously identified as CPE positive
  • Patients in recent contact with a known CPE carrier
 

Why Test with Fast PCR?

Fast and accurate PCR testing for the “BIG 5” carbapenemase gene families with the GeneXpert® system and Xpert® Carba-R test provides standardised, on-demand, and actionable results in 50 minutes, enabling healthcare systems to better manage the risk of CPE outbreaks, with potential to improve patient outcomes and minimise avoidable healthcare costs.6

 

The UK Government’s 2024 AMR National Action Plan aims to prevent any increase in Gram-negative bloodstream infections and highlights the critical need for rapid and accurate diagnostics in reducing the incidence of AMR.7

 

To support NHS Trusts, new national guidelines have been published which include the use of PCR alongside other methodologies to support screening efforts, and using diagnostics more generally to help guide prescribing.3,8

 

Fast PCR Testing for CPE with Cepheid

"The introduction of rapid molecular testing for CPE allowed us to shorten the time to result to a matter of hours instead of days, identify patients quickly and take the necessary precautions quickly." 

 


Dr. Tim Neal

Infection Control Doctor at Liverpool Clinical Laboratories

Xpert® Carba-R

Detection and differentiation of the “BIG 5” carbapenemase gene families in 50 minutes. 


Impact:

  • Improved bed & isolation management6

  • Reduced transmission & outbreaks6

  • Reduced colonisation & infection rates9

  • Reduced service disruption & costs10

GeneXpert® Systems

Our GeneXpert® family of systems have set a new standard in workflow flexibility, 24/7 accuracy, and user-friendly design.

 

Our engaging platform delivers:

  • On-demand and random-access walkway testing
  • Unique scalability and flexible design from 2-80 modules
  • Simplified workflow
  • Easy to maintain
  • Full connectivity

 

>30 CE-IVD Tests, One GeneXpert System for Consolidated AMR PCR Testing

 

COVID-19, Flu & RSV

Results in 36 minutes

Carbapenem-resistant Bacteria

Results in 50 minutes

C. difficile

Results in 43 minutes

Group B Streptoccoccus

Results in 56 minutes

MRSA

Results in 47 minutes^

TB & Resistance

Results in <90 minutes

Norovirus

Results in 60 minutes#

Vancomycin-resistant Bacteria

Results in 48 minutes

 

Choose Cepheid as your Trusted Diagnostics NHS Partner Today

Over the last 28 years, Cepheid has partnered with many hospitals, clinics, and laboratories around the world with more than 50,000 systems installed and millions of tests performed, including ~2 million PCR tests delivered to NHS hospitals each year11, changing the lives of patients.

 

With our solutions, your healthcare organisation can potentially reduce costs, streamline operations, and maximise productivity while prioritising patient health.

 

Download CPE Infographic

Speak to our experts about your stewardship and outbreak prevention plan

I would like to be part of the Cepheid Community and I understand and consent to receive information about products and services, invitations to virtual and in-person events such as workshops and webinars and educational content from Cepheid and similar information from Cepheid’s affiliates and representatives.

*required fields
Cepheid respects your privacy, and values the relationship with our customers, partners, and associates. Your personal data may be processed by Cepheid, its affiliates, representatives and other Danaher companies for business and marketing purposes. You can review Cepheid Privacy Policy online for additional information on your rights and how we use and share personal data we collect on our websites and other channels. Your consent to receiving Cepheid news can be withdrawn at any time. Building a relationship of trust is important to us and we will happily help with any questions on your personal data processing addressed to Privacy.officer@cepheid.com

CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.

^ For positive MRSA results with early assay termination. Otherwise, full runtime is 70 minutes.
# For positive Norovirus results with early assay termination. Otherwise, full runtime is 90 minutes.

1. Patel B, et al. Carbapenemase-producing Enterobacterales: a challenge for healthcare now and for the next decade. IPIP. 2020 Sep;2(3):100089. 2. Otter J, et al. Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective. CMI. 2016 Oct;23(3):188-196.

3. UKHSA—Framework of actions to contain carbapenemase-producing Enterobacterales (CPE), September 2022.

4. Tischendorf J, et al. Risk of infection following colonization with carbapenem-resistant Enterobacteriaceae: A systematic review. Am J Infect Control. 2016 May;44(5):539-43.

5. UKHSA. English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) Report 2022 to 2023.

6. Corless C, et al. Impact of different carbapenemase-producing Enterobacterales screening strategies in a hospital setting.IPIP. 2020 May;3(2):100011

7. UK Gov Policy Paper. Confront antimicrobial resistance 2024 to 2029. 8. National Institute for Health and Care Excellence (NICE). Ceftazidime with avibactam for treating severe drug-resistant Gram-negative bacterial infections. Draft guidance.

9. Zhou M, et al. Active surveillance of carbapenemase-producing organisms (CPO) colonization with Xpert® Carba-R assay plus positive patient isolation proves to be effective in CPO containment. Front Cell Infect Microbiol. 2019 May;14(9):162.

10. Birgand G, et al. Cost associated with implementation of a strict policy for controlling spread of highly resistant microorganisms in France. BMJ Open. 2016 Jan;6:e009029.

11. 2023 Internal data analysis actual 1.9.

About Cepheid

Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid's broad test portfolio spans respiratory infections, blood virology, women's and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company's solutions deliver actionable results where they are needed most from central laboratories and hospitals to near patient settings.

For more information, visit www.cepheid.com

© 2025 Cepheid. All Rights Reserved.